Business, energy, technology, markets and global industry news from Business News Today

chronic obstructive pulmonary disease

PharmaDeviceNews chronic obstructive pulmonary disease
Representative image: Respiratory medicine deal discussion highlighting Sino Biopharmaceutical’s AstraZeneca TQC3721 licensing agreement and expanded GSK inhaler commercialization rights in China.
Pharma & Biotech

Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals

Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China

Read More
A pulmonologist reviews lung imaging as an older patient uses an inhalation device, reflecting Kither Biotech’s effort to develop KIT2014 as a differentiated inhaled therapy for COPD and other chronic respiratory diseases. Representative image.
Pharma & Biotech

Can Kither Biotech turn KIT2014 into a differentiated inhaled therapy for COPD?

KIT2014 cleared its first human safety study with no measurable systemic exposure, but Kither Biotech must now prove that its peptide can improve lung function and inflammation in patients.

Read More
Representative image: A nebulized respiratory therapy setup illustrates the clinical focus behind AeroRx Therapeutics’ AERO-007 Phase 2a COPD data, as researchers evaluate whether once-daily LABA+LAMA nebulized treatment can address persistent delivery challenges in chronic obstructive pulmonary disease care.
Pharma & Biotech

Can AeroRx turn nebulized COPD treatment into a first-line dual bronchodilator category?

COPD care relies on handheld inhalers, but many patients struggle with delivery. AeroRx is testing whether nebulized dual therapy can close that gap.

Read More
Representative image: A generic inhaler device in a clinical research setting, illustrating Transpire Bio’s FDA-accepted ANDA filing for a proposed generic high-strength Trelegy Ellipta alternative for asthma and COPD treatment.
Pharma & Biotech

What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition

Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.

Read More
Representative image of a clinician reviewing lung CT scans and noninvasive sputum-based testing, as bioAffinity Technologies reports rising CyPath Lung adoption and growing interest in early lung cancer diagnostic tools.
Medical Devices & Diagnostics

Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question

CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.

Read More
Pharma & Biotech

AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco

AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.

Read More
Representative image: A respiratory specialist discusses lung health and biologic treatment options with a COPD patient, aligned with our coverage of GSK’s Nucala approval for eosinophilic COPD in China.
Pharma & Biotech

GSK secures China NMPA approval for Nucala in eosinophilic COPD, targeting hospitalisation risk

GSK PLC (LSE/NYSE: GSK) has received regulatory approval from the National Medical Products Administration of China for Nucala (mepolizumab) as an add-on maintenance therapy for adults with eosinophilic chronic obstructive pulmonary disease (COPD) inadequately controlled on inhaled triple therapy. The greenlight marks a strategic respiratory expansion for GSK in the world’s largest COPD market and

Read More